Literature DB >> 19565180

A chronic myeloid leukemia patient with atypical karyotype and BCR-ABL e13a3 transcript caused by complex chromosome rearrangement.

Masayoshi Masuko1, Tatsuo Furukawa2, Takashi Abe3, Reiko Wada4, Soichi Maruyama5, Toshiki Kitajima3, Yasuhiko Shibasaki3, Ken Toba3, Masahiko Okada4, Yoshifusa Aizawa3.   

Abstract

Philadelphia (Ph) chromosome as a result of t (9; 22) (q34; q11) is observed in more than 90% of chromic myeloid leukemia (CML) patients. Cases in which the typical Ph chromosome is not visible at the karyotype level comprise 5-10% of CML patients. CML cases with fusion transcripts such as e13a3 in which ABL exon 3 rather than exon 2 has fused to BCR are very rare. Such reported cases with the e13a3 transcript show the Ph chromosome on karyotype analysis. We reported an atypical karyotype CML patient with the e13a3 BCR-ABL transcript caused by complex translocation. Fluorescence in situ hybridization (FISH) analysis of the metaphase led to a precise cytogenetical characterization. The patient showed favorable response to imatinib, and achieved major molecular responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19565180     DOI: 10.1007/s12185-009-0368-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  14 in total

Review 1.  The molecular biology of chronic myeloid leukemia.

Authors:  M W Deininger; J M Goldman; J V Melo
Journal:  Blood       Date:  2000-11-15       Impact factor: 22.113

2.  CML with an e1a3 BCR-ABL fusion: rare, benign, and a potential diagnostic pitfall.

Authors:  Haifa-Kathria Al-Ali; Sabine Leiblein; Ines Kovacs; Evelin Hennig; Dietger Niederwieser; Michael W N Deininger
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

3.  Fused transcript of abl and bcr genes in chronic myelogenous leukaemia.

Authors:  E Shtivelman; B Lifshitz; R P Gale; E Canaani
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

4.  A rare, in-frame BCR-ABL fusion (e13a3) in a patient with an aggressive chronic myeloid leukaemia.

Authors:  Ivone B Otazú; María Belén Rivero; Renata Olício; Augusto Pinto; Ilana Zalcberg; Héctor N Seuánez
Journal:  Acta Haematol       Date:  2002       Impact factor: 2.195

5.  Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.

Authors:  Alfonso Quintas-Cardama; Hagop Kantarjian; Moshe Talpaz; Susan O'Brien; Guillermo Garcia-Manero; Srdan Verstovsek; Mary Beth Rios; Kimberly Hayes; Armand Glassman; B Nebiyou Bekele; Xian Zhou; Jorge Cortes
Journal:  Blood       Date:  2004-11-30       Impact factor: 22.113

6.  Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript.

Authors:  Barbara Pienkowska-Grela; Renata Woroniecka; Iwona Solarska; Kinga Kos; Anna Pastwińska; Lech Konopka; Miroslaw Majewski
Journal:  Cancer Genet Cytogenet       Date:  2007-04-15

Review 7.  Chronic myelogenous leukemia with e13a3 (b2a3) type of BCR-ABL transcript having a DNA breakpoint between ABL exons a2 and a3.

Authors:  Li-Gen Liu; Hideo Tanaka; Kinro Ito; Taiichi Kyo; Takuo Ito; Akiro Kimura
Journal:  Am J Hematol       Date:  2003-12       Impact factor: 10.047

Review 8.  Heterogeneity of the breakpoint in the ABL gene in cases with BCR/ABL transcript lacking ABL exon a2.

Authors:  S Iwata; S Mizutani; S Nakazawa; J Yata
Journal:  Leukemia       Date:  1994-10       Impact factor: 11.528

9.  Imatinib improves but may not fully reverse the poor prognosis of patients with CML with derivative chromosome 9 deletions.

Authors:  Brian J P Huntly; Francois Guilhot; Alistair G Reid; George Vassiliou; Evelin Hennig; Christina Franke; Jennie Byrne; Andre Brizard; Dietger Niederwieser; Julie Freeman-Edward; Gavin Cuthbert; Nick Bown; Richard E Clark; Elizabeth P Nacheva; Anthony R Green; Michael W N Deininger
Journal:  Blood       Date:  2003-05-15       Impact factor: 22.113

10.  Chronic myeloid leukemia with an e13a3 BCR-ABL fusion: benign course responsive to imatinib with an RT-PCR advisory.

Authors:  David S Snyder; Ross McMahon; Sandra R Cohen; Marilyn L Slovak
Journal:  Am J Hematol       Date:  2004-02       Impact factor: 10.047

View more
  5 in total

1.  Molecular response to imatinib in chronic myeloid leukaemia with a variant e13a3 BCR-ABL1 fusion.

Authors:  Sarah L McCarron; Stephen E Langabeer; Karen Bolger; Karl Haslam; Mireille Crampe; Johanna Kelly; Ruth Morrell
Journal:  Med Oncol       Date:  2015-01-13       Impact factor: 3.064

2.  A rare chronic myeloid leukemia case with Philadelphia chromosome, BCR-ABL e13a3 transcript and complex translocation involving four different chromosomes.

Authors:  Walid Al Achkar; Abdulsamad Wafa; Bashar Yousef Ali; Marina Manvelyan; Thomas Liehr
Journal:  Oncol Lett       Date:  2010-09-01       Impact factor: 2.967

3.  Chronic Myeloid Leukemia With Rare Variant b2a3 (e13a3) BCR-ABL1 Fusion.

Authors:  Jihye Ha; June Won Cheong; Saeam Shin; Seung Tae Lee; Jong Rak Choi
Journal:  Ann Lab Med       Date:  2016-05       Impact factor: 3.464

4.  Chronic myeloid leukemia with a rare fusion transcript, b2a3 (e13a3) BCR-ABL1: A report of four cases from India.

Authors:  Sudha Sazawal; Sunita Chhikara; Kanwaljeet Singh; Rekha Chaubey; Manoranjan Mahapatra; Tulika Seth; Renu Saxena
Journal:  South Asian J Cancer       Date:  2019 Apr-Jun

5.  Atypical presentation of patients with chronic myeloid leukemia in chronic phase-Case report.

Authors:  Florian Ramdohr; Alice Fabarius; Bettina Maier; Daniela Bretschneider; Anna Jauch; Astrid Monecke; Klaus H Metzeler; Johannes W G Janssen; Richard F Schlenk; Sabine Kayser
Journal:  Front Oncol       Date:  2022-08-29       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.